key: cord-0736283-nq16jcs9
authors: Acharya, Priyamvada; Williams, Wilton; Henderson, Rory; Janowska, Katarzyna; Manne, Kartik; Parks, Robert; Deyton, Margaret; Sprenz, Jordan; Stalls, Victoria; Kopp, Megan; Mansouri, Katayoun; Edwards, Robert J; Meyerhoff, R. Ryan; Oguin, Thomas; Sempowski, Gregory; Saunders, Kevin; Haynes, Barton F.
title: A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies
date: 2020-06-30
journal: bioRxiv
DOI: 10.1101/2020.06.30.178897
sha: 05b17094190778717522c1ab3f5f4ff349ad4826
doc_id: 736283
cord_uid: nq16jcs9

The COVID-19 pandemic caused by SARS-CoV-2 has escalated into a global crisis. The spike (S) protein that mediates cell entry and membrane fusion is the current focus of vaccine and therapeutic antibody development efforts. The S protein, like many other viral fusion proteins such as HIV-1 envelope (Env) and influenza hemagglutinin, is glycosylated with both complex and high mannose glycans. Here we demonstrate binding to the SARS-CoV-2 S protein by a category of Fab-dimerized glycan-reactive (FDG) HIV-1-induced broadly neutralizing antibodies (bnAbs). A 3.1 Å resolution cryo-EM structure of the S protein ectodomain bound to glycan-dependent HIV-1 bnAb 2G12 revealed a quaternary glycan epitope on the spike S2 domain involving multiple protomers. These data reveal a new epitope on the SARS-CoV-2 spike that can be targeted for vaccine design. Highlights Fab-dimerized, glycan-reactive (FDG) HIV-1 bnAbs cross-react with SARS-CoV-2 spike. 3.1 Å resolution cryo-EM structure reveals quaternary S2 epitope for HIV-1 bnAb 2G12. 2G12 targets glycans, at positions 709, 717 and 801, in the SARS-CoV-2 spike. Our studies suggest a common epitope for FDG antibodies centered around glycan 709.

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019 and rapidly spread, causing a global pandemic of a severe acute respiratory syndrome . The SARS coronavirus-2 (SARS-CoV-2) utilizes a heavily glycosylated spike (S) protein to bind its host receptor, angiotensin-converting enzyme 2 (ACE2), and mediate cell entry and fusion (1). The S protein is a trimeric class I fusion protein composed of two functional subunits responsible for receptor binding (S1 subunit) and membrane fusion (S2 subunit) (2, 3) .

The surface of the virally encoded S protein is covered by host-derived glycans with each trimer encoding 66 N-linked glycosylation sites (4) .

Viral fusion proteins such as the spike proteins of diverse Coronaviruses, the HIV-1 envelope (Env) and influenza hemagglutinin (HA), are typically covered with high mannose and complex glycans (5, 6) . Viruses rely on host glycosylation machinery to synthesize and express glycans, which cover the surface of proteins exposed on the virus and shield conserved neutralization epitopes from immune surveillance. While genetic and somatic diversities can preclude targeting protein epitopes for broad-spectrum neutralization, viruses may display common carbohydrate moieties that can be targeted by glycan binding agents. Indeed, targeting glycan moieties has been proposed as a general strategy for broad-spectrum virus neutralization (7) (8) (9) . While one concern with this general concept is that the glycan targeting agents may have unfavorable cross-reactivity with human tissue by binding host carbohydrate moieties, heavily glycosylated viral proteins, of which HIV-1 Env is an example, have significant population of unprocessed oligomannose-type glycans that are not usually observed at high abundance on secreted mammalian glycoproteins (10, 11) . This divergence from host cell glycosylation and the 'non-self' nature of these oligomannose glycans represent immunogenic targets, and indeed a number of anti-HIV-1 broadly neutralizing antibodies (bnAbs) have been isolated that specifically target gp120 glycans as part of their epitope (12) (13) (14) .

Site-specific glycan analysis of the SARS-CoV-2 spike protein demonstrated 28% of oligomannose-type glycans on the S protein surface (4) . Here, we raised the hypothesis that the glycan shield of the SARS-CoV-2 spike protein can be targeted by HIV-1 glycan-reactive antibodies. We tested SARS-CoV-2 S protein for binding by HIV-1 bnAb 2G12 that binds a glycan-only epitope on the HIV-1 Env (12, 15, 16) , as well as by a panel of Fab-dimerized glycan-reactive (FDG) antibodies. We have recently demonstrated that FDG antibodies are common in the HIV-1 uninfected B cell repertoire, and they bound high mannose glycans on HIV-1 Env, yeast and other environmental antigens (17) .

In a companion manuscript (17), we described highly prevalent FDG antibodies that target the high mannose glycan shield of the HIV-1 Env. Here, we test members of this category of antibodies for binding to the SARS-CoV-2 spike (S) protein. A SARS-CoV-2 S protein ectodomain construct incorporating residues 1-1208 of the SARS-CoV-2 S protein and harboring two stabilizing proline mutations in the S2 domain, a foldon trimerization domain, as well as C-terminal Twin Streptactin and His tags, were expressed and purified as described previously from HEK-293F cells ( Figure S1 ) (2) . We tested three different groups of FDG antibodies -(1) FDG antibodies that were isolated from SHIV-infected macaques and shown to broadly neutralize HIV-1 isolates (DH851.1 -DH851.3, and DH1003.2); (2) FDG precursor antibodies that were isolated from a HIV naïve human (DH1005), and SHIV infected (DH898.1 and DH898.4) or HIV Env vaccinated (DH717.1 -DH717.4, and DH501) macaques; and (3) antibody 2G12 that forms a subcategory on its own as the only variable heavy (VH) domainswapped FDG antibody known to date. Antibody 2G12 is a bnAb that neutralizes heterologous HIV-1 isolates and binds to a conformational glycan cluster on HIV-1 Env (15, 18, 19) .

To test whether the FDG antibodies that bind the HIV-1 Env glycan shield can also recognize the SARS-CoV-2 spike we performed ELISA and SPR assays (Figures 1 and S2-S8 ). As a positive control in the ELISA assays we included antibody D001 (see methods) that binds the receptor binding domain (RBD) of SARS-CoV-1 and SARS-CoV-2, and as a negative control, antibody CH65 (20) that binds the influenza hemagglutinin. We observed binding of the S protein to the RBD-directed antibody D001, whereas no binding was observed for negative control antibody, CH65. All FDG antibodies tested bound the SARS-Cov-2 spike to varying degrees (Figures 1, S2 and S3) . To determine if these antibodies were targeting glycan epitopes on the SARS-CoV-2 S protein, we tested binding of the antibodies to the S protein in the presence of a high-mannose glycan (D-mannose) (Figures 1, S2 To gain insight into the epitope on the SARS-CoV-2 spike ectodomain targeted by the FDG antibodies we chose 2G12 for structural determination in complex with the SARS-2 spike ectodomain. While the non-domain-swapped FDG antibodies exist as mixtures of Y-and Ishaped forms (17) , the VH domain-swapped 2G12 presents a 100% I-shaped population that can be separated from its intermolecular dimer form by size exclusion chromatography (21) and digested using papain to yield a stable domain-swapped Fab dimer amenable to structural studies ( Figure S7 ) (12, 15, 18, 19) . The 2G12 Fab obtained by papain digestion of the 2G12 IgG ( Figure S7 ) bound to SARS-CoV-2 spike with affinity of ~313 nM (Figure S8) , and on-and off-rates of 3.5 X 10 4 M -1 s -1 and 1.19 X 10 2 s -1 , respectively.

The FDG antibodies in Figure 1 as well as the HIV-1 bnAb 2G12 were tested in a SARS-CoV-2 plaque reduction neutralization assay and were all negative starting at 50 µg/ml (data not shown). Importantly, in none of the assays were enhanced numbers of viral plaques seen with the addition of FDG antibodies.

To visualize the epitope of 2G12 bound to the SARS-CoV-2 spike we determined a cryo-EM structure of the 2G12 Fab bound to a stabilized SARS-CoV-2 ectodomain construct (2) (Figures 2-6, S9 and S10; Table S1 ). The cryo-EM dataset obtained from 6804 micrographs showed considerable compositional heterogeneity, revealing populations of unliganded spike, as well as spike bound to 2G12 at 1, 2 or 3 of it binding sites ( Figure S9) . The 2G12-bound spike was ~15% of the total population. We obtained cryo-EM reconstructions of the SARS-CoV-2 S protein bound to a single 2G12 Fab at 3.3 Å from ~ 108,000 particles, and S protein bound to two 2G12 Fabs at 3.2 Å resolution from ~110,000 particles. (Figure S9) . We also observed a smaller population (~42,000 particles) that showed occupancy at all three binding sites, although the 2G12 density at one of the sites was substantially weaker than at the other two. Even upon extensive 3D classification of this population, the weaker density at the third site remained suggesting that this weak density was due to flexibility of the bound 2G12 rather than partial occupancy. To maximize the resolution of the 2G12 interface with the SARS-CoV-2 spike, we performed 3D refinement by combining all 2G12-bound particles and using a mask that focused the refinement on the S protein and one 2G12 Fab. On doing so, we obtained a 3.1 Å reconstruction of 2G12 Fab bound to the SARS-CoV-2 spike (Figures 2 and S9 ; Table S1 ).

Fitting this map with the coordinates for the SARS-CoV-2 spike (PDB 6VXX) (3) and 2G12 Fab2 (PDB 6N35) (12), followed by iterative coordinate refinement and model building (22, 23) yielded a model for 2G12 Fab2 bound to the SARS-CoV-2 spike that was used for further analysis.

The local resolutions of the cryo-EM reconstruction spanned a range from 2. The VH domain swapped configuration of the 2G12 Fab-dimer (Fab2) was well-defined in the electron density of the bound 2G12 (Figure 2A and B) . This unique domain-swapped architecture that has been described previously in a number of high-resolution structures solved using x-ray crystallography or cryo-EM (12, 19, (24) (25) (26) (27) , results in the creation of two secondary binding sites on either side of the VH/VH interface, in addition to the primary binding site at the VH/VL interface (19) . The cryo-EM reconstruction of the Fab2 fragment of 2G12 bound to the SARS-Cov-2 spike revealed a quaternary epitope for 2G12 in the S2 subunit of the SARS-CoV-2 spike with glycans from different protomers clustered together to form the 2G12 epitope (Figures 2-4) . Three S protein glycans were the primary contributors to the 2G12 binding epitope -glycans 717 and 801 from one protomer and glycan 709 from the adjacent protomer (Figures 3-5) . The 2G12 Fab2 interaction with the SARS-CoV-2 spike buried a 1,500 Å 2 area at its interface with the epitope composed entirely of N-linked glycans with the primary binding sites; each at one of the VH/VL interfaces, contacting glycans at positions N709 and N717 ( Figures 1A-1C ; see Figure S2 for glycan nomenclature). One of the two secondary binding sites created as a result of the VH/VH domain swapping contacted the glycan at positions N801 ( Figures 3 and 4 ).

Because glycan-only epitopes are expected to be more mobile than a protein epitope we investigated the extent of disorder and motion in the position of the 2G12 bound to the S protein. Heterogeneous 3D classification performed on the cryo-EM dataset using a mask including the 2G12 density and S2 density, and excluding the S1 and the HR2 regions, revealed two distinct 2G12 orientations that were related by a 9-degree angular displacement about a hinge at glycan 709 ( Figure 5A and B) . To test the importance of this residue that appeared to be a pivot point for the bound 2G12, a N709A glycan deletion mutant was expressed and purified, and confirmed by NSEM to contain well-dispersed and properly folded spike particles ( Figure S1 ). Deletion of the glycan at position 709 resulted in abrogation of 2G12 Fab binding, thus confirming that glycan 709 is critical for the binding of 2G12 to the SARS-Cov-2 spike ( Figure 5C ).

We next tested the binding of the panel of non-domain-swapped FDG antibodies to the N709A glycan-deleted mutant in an SPR assay. The N709 glycan deletion either abrogated or substantially reduced the binding of the FDG IgGs tested (Figures 5D and S11 ), thus suggesting a common epitope on the SARS-CoV-2 spike that is recognized by FDG antibodies.

The VH domain-swapped 2G12 has been shown to bind isolated Man9 glycans, and to HIV-1 Env. In this study we demonstrate that 2G12 can also bind the SARS-CoV-2 S protein ( Figure 6A -D) (12, 19) . While 2G12 can recognize free mannose in its non-domain-exchanged form, it only binds the HIV-1 glycan shield if domain-exchanged, thus highlighting the importance of avidity for its interactions with glycan clusters (27) . The structure of 2G12 bound to HIV-1 Env revealed binding sites for 4 HIV-1 Env glycans on 2G12 (15, 18) , one each at the two primary binding sites at the VH/VL interface and the other two at the secondary sites at the VH/VH interface created as a result of domain-swapping (Figures 6B). Consistent with its glycan-only epitope, 2G12 binding to a soluble HIV-1 Env construct is inhibited by D-mannose ( Figure 6D ). In the structure of 2G12 Fab2 bound to the SARS-CoV-2 S protein, only 3 of these glycan binding sites on 2G12 were occupied by spike glycans ( Figure 6C ) and, while 2G12 showed robust glycan-dependent binding to the SARS-CoV-2 S protein, the binding was weaker than for the HIV-1 Env ( Figure 6D ). Another noteworthy difference between the binding of 2G12 to HIV-1 Env versus is binding to SARS-CoV-2 S is that on the HIV-1 Env all the binding glycans come from a single gp120 monomer in the HIV-1 Env trimer, whereas in the SARS-CoV-2 S protein the binding site is quaternary and the 2G12-binding glycans at each site are contributed by two of the three protomers, making this one of the first examples of a quaternary epitope spanning multiple protomers on the SARS-CoV-2 S protein (28) , and the first in the S2 domain.

In this paper we demonstrated that a category of prevalent glycan-reactive antibodies, termed FDG antibodies, can bind to high mannose glycans on the surface of the SARS-CoV-2 spike protein. FDG antibodies can bind to isolated high mannose glycans (17, 29) as well as high mannose glycans on HIV-1 and on fungal pathogens such as Candida albicans and Cryptococcus neoformans (17, 30) . With HIV-1 infection in humans or SHIV infection of macaques, FDG antibodies can be affinity matured to achieve heterologous breadth. While the 2G12 HIV-1 broadly neutralizing antibody has VH domain swapped architecture (12) , this architecture was so unique that 2G12 was the only antibody of its kind known for a long time.

However, we recently discovered non-domain-swapped FDG antibodies that dimerize without VH domain swapping and are capable of broad HIV-1 broad neutralization, as shown for the DH851 IgG clonal lineage antibodies (17) . Here we show, in addition to 2G12 binding, that VH domain swapping is also not required for FDG antibody recognition of the SARS-CoV-2 spike protein as demonstrated by its binding to the non-domain-swapped FDG antibodies. While the HIV-1 Env-reactive FDG antibodies tested in this study do not neutralize SARS-CoV-2, the demonstration that a common epitope for FDG antibodies exists on the surface of the SARS-CoV-2 spike, raises the hypothesis that SARS-CoV-2 infection may enjoin FDG precursors and select for FDG affinity matured antibodies that evolve the capacity to neutralize SARS-CoV-2 via glycan recognition.

That FDG precursors are common in the human B cell repertoire demonstrates that they are not deleted due to immune tolerance mechanisms (17) . It has been previously postulated that the 2G12 and other glycan-reactive HIV-1 antibodies are rare due to reactivity with selfglycans (31) . In this regard, select HIV-1 glycan reactive antibodies have been shown to react with the surface of immune cell subsets (32) . Whether immune tolerance mechanisms will limit the affinity maturation of FDG antibodies to potently neutralize SARS-CoV-2 is yet unknown.

These data along with the companion paper describing the category of FDG anti-HIV-1 antibodies raise the hypothesis that preexisting antibodies raised by high mannose-containing environmental antigens such as fungi or host molecules can be co-opted by HIV-1 Env to become HIV-1 broadly neutralizing antibodies. Here we propose this same set of FDG precursor antibodies might be able to be targeted by the S protein of SARS-CoV-2 in the setting of COVID-19 disease or vaccination and induce SARS-CoV-2 neutralizing antibodies. It will be of interest to determine if FDG category of S-protein-reactive antibodies that can neutralize SARS-CoV-2 can be isolated from COVID-19 infected or vaccinated individuals. In this regard, Ng et al have demonstrated pre-existing S2 IgG antibodies to SARS-CoV-2 S-protein likely induced by human CoVs that cause common cold syndromes. Some of these sera were able to neutralize SARS-CoV-2 (33). However, it remains unknown if such pre-existing S2-protein antibodies are glycan reactive.

In summary, we demonstrate the reactivity of a pool of glycan-reactive antibodies with a quaternary epitope on the SARS-CoV-2 spike protein.

A key study will be to determine if FDG antibodies can be recruited by vaccination to develop into antibodies that can play a preventive role in protection from SARS-CoV-2 infection. 

The SARS-CoV-2 ectodomain constructs were produced and purified as described previously (2) . Briefly, a gene encoding residues 1−1208 of the SARS-CoV-2 S (GenBank: MN908947) with proline substitutions at residues 986 and 987, a "GSAS" substitution at the furin cleavage site (residues 682-685), a C-terminal T4 fibritin trimerization motif, an HRV3C protease cleavage site, a TwinStrepTag and an 8XHisTag was synthesized and cloned into the mammalian expression vector pαH. All mutants were introduced in this background. expression plasmids encoding the ectodomain sequence were used to transiently transfect FreeStyle293F cells using Turbo293 (SpeedBiosystems). Protein was purified on the sixth day post transfection from the filtered supernatant using StrepTactin resin (IBA) ( Figure S1 ). Affinity purified protein was run over a Superose 6/300 increase column. The purified protein was flash-frozen in liquid nitrogen and stored at -80° C.

Rhesus FDG mAbs DH851.1 -DH851.3, DH1003.2, DH898.1 and DH898.4, DH717.1 -DH717.4, and DH501 and human FDG antibody DH1005 were expressed as previously described (17) . Antibody 2G12 was obtained from three sources, either produced from two sources as described from the original sequence (17) sugar. SARS-CoV-2 trimeric spike protein was captured by streptavidin to individual wells of a 384-well plate, and serially diluted mAbs were tested for binding. ELISA binding assays were optimized to use SARS-CoV-2 spike protein that was aliquotted and frozen upon production; desired aliquots of frozen spike protein were thawed once at 37 o and stored overnight at room temperature. SARS-CoV-2 spike protein, and Man9-V3 and Aglycone V3 peptides were captured via streptavidin on Nunc-absorb ELISA plates using PBS-based buffers and assay conditions as previously described (34, 35) . HIV-1 CH505TF SOSIP trimer and commerciallyobtained constructs of SARS-CoV-2 spike ectodomain (S1+S2 ECD, S2 ECD and RBD) (Sino Biological Inc cat# 40589-V08B1 and 40590-V08B respectively and RBD from Genescript cat# Z03483) were captured using mouse anti-AVI-tag mAb (Avidity LLC, Aurora, CO). In brief, we coated 30ng of streptavidin in 15µl at 2µg/ml or 30 ng of mouse anti-AVI-tag mAb in 15µl at 2µg/ml per well of a 384-well Nunc-absorb ELISA plate, sealed and incubated overnight at 4 o C.

SARS-CoV-2 spike protein (2µg/ml) were added to streptavidin in 10µl per well of a 384-well plate for one hour at room temperature to facilitate protein capture. HIV-1 CH505TF SOSIP trimer and SARS-CoV-2 S1+S2 ECD, S2 ECD and RBD spike proteins (2 µg/ml) were added to anti-AVI mAb in 10µl per well of a 384-well plate for one hour at room temperature to facilitate ELISAs using superblock were previously described (36) . Moreover, whereas the 2G12 from Polymun bound to S protein in surface plasmon reasonance, it was less potent than the recombinantly expressed 2G12 antibodies, and did not bind well in ELISA. Commercial 2G12 from Polymun is provided in a maltose (mannose) buffer.

The neutralization assays were performed using SARS-CoV-2 isolate USA-WA1/2020, RVU Lot: NR52281-20200314. Source material supplied by BEI resources, catalog number NR-52281. Data are reported as PRNT50 or 50% reduction in foci count relative to back titer input verification. Endpoint titer of a given dilution series is reported as the concentration of the lowest continuous dilution with a foci count less than or equal to the 50% neutralization cutoff. All experimental samples were assayed as at least duplicate dilution series. Virus input and internal assay controls were within accepted tolerances.

A 100 µg/ml final concentration of the spike was made in 1:1 ratio of 0.15% glutaraldehyde in HBS pH 7.4 (20mM HEPES, 150mM NaCl) to 10% Glycerol in HBS, pH 7.4. After 5 min incubation Tris pH 7.4 was added from a 1M stock to a final concentration of 0.075M to quench the glutaraldehyde and incubated for 5min. The carbon coated grids (CF300-cu, EMS) were glow discharged for 20sec at 15mA. A 5 µl of sample incubated on grid for 10-15 sec, blotted and then stained with 2% uranyl formate. The antibodies were diluted in 0.02% Ruthenium red in HBS pH 7.4. After 5-10min incubation, a 5 µl droplet loaded on a glow discharged carbon coated grid, briefly rinsed with dH2O and then stained with 2% uranyl formate. Images were obtained with a Philips EM420 electron microscope operated at 120 kV, at 82,000× magnification and a 4.02 Å pixel size. The RELION program was used to perform class averaging of the single-particle images.

The binding FDG antibodies to SARS-CoV-2 spike was assessed by surface plasmon resonance on Biacore T-200 (GE-Healthcare) at 25°C with HBS-EP+ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.05% surfactant P-20) as the running buffer. Binding was measured in two different formats. In the first format ( Figures S4 and S5A) , SARS-CoV-2 spike was captured on a SA chip and binding response was measured by flowing over IgG solutions.

The surface was regenerated between injections by flowing over 1M NaCl in 50mM NaOH solution for 10s with flow rate of 100µl/min. In the second format ( Figure S5B The data were fit to a 1:1 Langmuir binding model.

Purified SARS-CoV-2 spike preparations were diluted to a final concentration of ~1 mg/mL in 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN3, were mixed with 6-fold molar excess of 2G12 Fab and incubated for 2 hours at room tempearture. 2.5 uL of protein was deposited on a CF-

Discharge Cleaning System. After a 30 s incubation in >95% humidity, excess protein was blotted away for 2.5 seconds before being plunge frozen into liquid ethane using a Leica EM GP2 plunge freezer (Leica Microsystems).

Cryo-EM imaging was performed on a FEI Titan Krios microscope (Thermo Fisher Scientific) operated at 300 kV. Data were acquired with a Gatan K3 detector operated in counting mode using the Leginon system. The K3 experimental parameters are 2500 ms exposure with 50 frames at 50 ms framerate with a total dose of 66.43 e-/A2 and a pixel size of ~1.058Å/px. This system was also energy-filtered with a slit width of 20 eV. A total of 6804 images were collected.

Cryo-EM image quality was monitored on-the-fly during data collection using automated processing routines. Individual frames were aligned and dose-weighted using MotionCor2 (37) implemented within the Appion pipeline (38) . Data processing was performed within cryoSPARC (39) including particle picking, multiple rounds of 2D classification, ab initio reconstruction, heterogeneous and homogeneous map refinements, and non-uniform map refinements.

Heterogenous classifications were performed within RELION (40) using masks produced in Chimera.

Structure of the all 'down' state (PDB ID 6VXX) the previously published SARS-CoV-2 ectodomain, and a structure of the 2G12 Fab bound to Man1-2 (PDB ID 6N35) were used to fit the cryo-EM maps in ChimeraX. Coordinates were then fit manually in Coot (23) following iterative refinement using Isolde (22) and subsequent manual coordinate fitting in Coot.

Structure and map analysis was performed using PyMol and ChimeraX (41) .

The cryo-EM maps and fitted coordinates are in the process of being deposited to the electron microscopy database (EMDB) and the RCSB Protein Data Bank, respectively. The sequences of the FDG antibody heavy and light chain genes were deposited in GenBank as previously described (17, 29) Serially-diluted mAbs were tested for binding (also see Figure S2 and S3). Mouse anti-rhesus or goat antihuman IgG-HRP secondary antibodies were used to detect binding by rhesus or human mAbs, respectively. Binding was measured at absorbance of OD 450nm , whereas binding titers as Log area under the curve were reported in Figure S1 . 

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Site-specific glycan analysis of the SARS-CoV-2 spike

Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy

Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?

Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens

Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

Broad neutralization coverage of HIV by multiple highly potent antibodies

High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection

Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition

The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12

Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques

Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy

Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions

Broadly neutralizing human antibody that recognizes the receptorbinding pocket of influenza virus hemagglutinin

Structural basis for enhanced HIV-1 neutralization by a dimeric immunoglobulin G form of the glycan-recognizing antibody 2G12

ISOLDE: a physically realistic environment for model building into lowresolution electron-density maps

Features and development of Coot

Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12

A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity

Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike. bioRxiv

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates

Antibody 2G12 recognizes di-mannose equivalently in domain-and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged

Exploiting the defensive sugars of HIV-1 for drug and vaccine design

Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals

Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide

Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies

Potent and broad HIV-neutralizing antibodies in memory B cells and plasma

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

Appion: an integrated, database-driven pipeline to facilitate EM image processing

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

RELION: implementation of a Bayesian approach to cryo-EM structure determination

Meeting modern challenges in visualization and analysis

Commercially available constructs expressing the SARS-CoV-2 S1 and S2 extracellular domain (S1+S2 ECD), S2 domain (S2 ECD), and the receptor binding domain (RBD) were tested for binding by serial dilutions of mAbs; all mAbs were tested at a starting antibody concentration of 100µg/ml. Commercially available proteins were captured using mouse anti-AVI-tag mAb, so we also assessed background binding to only anti-AVI-tag coated plates